Axsome Therapeutics Inc (AXSM)

[smallbio]

Thanks for the info.

Do you believe STRIDE-1 topline readout push back is due to AXSM want to additional patients to satisfy safety data (300 patients total 200 for at least one year & 100 for at least two year)?

I thought the safety trial is open label.

I do think the planned MDD phase 3 trial has a higher chance to succeed based on the P2 data as P2 is with comparator arm (Wellbutrin) vs P2 is with placebo.